Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients

Barbara M. Brooks-Worrell, Rattan Juneja, Anushiruan Minokadeh, Carla J. Greenbaum, Jerry P. Palmer

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Type 1 diabetes is a cell-mediated autoimmune disease characterized by autoantibody and peripheral blood mononuclear cell (PBMC) reactivity to islet cell proteins. Type 2 diabetes is not an autoimmune disease but rather results from both insulin resistance and a nonautoimmune insulin secretory defect. There is, however, a group of phenotypic type 2 diabetic patients who have islet autoantibodies that are similar to those of type 1 diabetic patients. In this study, we investigated, using cellular immunoblotting, whether type 2 diabetic patients positive for islet autoantibodies have PBMC responses to islet proteins. We observed that autoantibody negative (Ab-) type 2 diabetic patients (n = 9) and normal control subjects (n = 12) demonstrated PBMCs responsive to 0-3 molecular weight regions. In contrast, autoantibody positive (Ab+) type 2 diabetic patients (n = 11) demonstrated PBMC responses to 3-18 molecular weight regions, similar to that of type 1 diabetic patients (responsive to 4-18 molecular weight regions). PBMCs from over 90% of the Ab+ type 2 and type 1 diabetic patients were observed to proliferate to islet proteins in the vicinity of 97 kDa. In contrast, 65-90% of type 1 diabetic patients had responsive PBMCs for islet proteins in most of the molecular weight regions, whereas + type 2 diabetic patients had PBMCs responsive to the same molecular weight proteins. Ab+ type 2 diabetic patients appear to be heterogeneous with respect to cellular reactivity to islet proteins. Some subjects demonstrate PBMC responses similar to those of 'classic' type 1 diabetic patients, whereas others have PBMC responses potentially distinct from type 1 diabetic patients.

Original languageEnglish (US)
Pages (from-to)983-988
Number of pages6
JournalDiabetes
Volume48
Issue number5
DOIs
StatePublished - 1999
Externally publishedYes

Fingerprint

Cellular Immunity
Antibodies
Proteins
Autoantibodies
Blood Cells
Molecular Weight
Autoimmune Diseases
Type 1 Diabetes Mellitus
Islets of Langerhans
Immunoblotting
Type 2 Diabetes Mellitus
Insulin Resistance
Insulin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. / Brooks-Worrell, Barbara M.; Juneja, Rattan; Minokadeh, Anushiruan; Greenbaum, Carla J.; Palmer, Jerry P.

In: Diabetes, Vol. 48, No. 5, 1999, p. 983-988.

Research output: Contribution to journalArticle

Brooks-Worrell, Barbara M. ; Juneja, Rattan ; Minokadeh, Anushiruan ; Greenbaum, Carla J. ; Palmer, Jerry P. / Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. In: Diabetes. 1999 ; Vol. 48, No. 5. pp. 983-988.
@article{fec26b2143644144ac16bfbca999aa73,
title = "Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients",
abstract = "Type 1 diabetes is a cell-mediated autoimmune disease characterized by autoantibody and peripheral blood mononuclear cell (PBMC) reactivity to islet cell proteins. Type 2 diabetes is not an autoimmune disease but rather results from both insulin resistance and a nonautoimmune insulin secretory defect. There is, however, a group of phenotypic type 2 diabetic patients who have islet autoantibodies that are similar to those of type 1 diabetic patients. In this study, we investigated, using cellular immunoblotting, whether type 2 diabetic patients positive for islet autoantibodies have PBMC responses to islet proteins. We observed that autoantibody negative (Ab-) type 2 diabetic patients (n = 9) and normal control subjects (n = 12) demonstrated PBMCs responsive to 0-3 molecular weight regions. In contrast, autoantibody positive (Ab+) type 2 diabetic patients (n = 11) demonstrated PBMC responses to 3-18 molecular weight regions, similar to that of type 1 diabetic patients (responsive to 4-18 molecular weight regions). PBMCs from over 90{\%} of the Ab+ type 2 and type 1 diabetic patients were observed to proliferate to islet proteins in the vicinity of 97 kDa. In contrast, 65-90{\%} of type 1 diabetic patients had responsive PBMCs for islet proteins in most of the molecular weight regions, whereas + type 2 diabetic patients had PBMCs responsive to the same molecular weight proteins. Ab+ type 2 diabetic patients appear to be heterogeneous with respect to cellular reactivity to islet proteins. Some subjects demonstrate PBMC responses similar to those of 'classic' type 1 diabetic patients, whereas others have PBMC responses potentially distinct from type 1 diabetic patients.",
author = "Brooks-Worrell, {Barbara M.} and Rattan Juneja and Anushiruan Minokadeh and Greenbaum, {Carla J.} and Palmer, {Jerry P.}",
year = "1999",
doi = "10.2337/diabetes.48.5.983",
language = "English (US)",
volume = "48",
pages = "983--988",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "5",

}

TY - JOUR

T1 - Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients

AU - Brooks-Worrell, Barbara M.

AU - Juneja, Rattan

AU - Minokadeh, Anushiruan

AU - Greenbaum, Carla J.

AU - Palmer, Jerry P.

PY - 1999

Y1 - 1999

N2 - Type 1 diabetes is a cell-mediated autoimmune disease characterized by autoantibody and peripheral blood mononuclear cell (PBMC) reactivity to islet cell proteins. Type 2 diabetes is not an autoimmune disease but rather results from both insulin resistance and a nonautoimmune insulin secretory defect. There is, however, a group of phenotypic type 2 diabetic patients who have islet autoantibodies that are similar to those of type 1 diabetic patients. In this study, we investigated, using cellular immunoblotting, whether type 2 diabetic patients positive for islet autoantibodies have PBMC responses to islet proteins. We observed that autoantibody negative (Ab-) type 2 diabetic patients (n = 9) and normal control subjects (n = 12) demonstrated PBMCs responsive to 0-3 molecular weight regions. In contrast, autoantibody positive (Ab+) type 2 diabetic patients (n = 11) demonstrated PBMC responses to 3-18 molecular weight regions, similar to that of type 1 diabetic patients (responsive to 4-18 molecular weight regions). PBMCs from over 90% of the Ab+ type 2 and type 1 diabetic patients were observed to proliferate to islet proteins in the vicinity of 97 kDa. In contrast, 65-90% of type 1 diabetic patients had responsive PBMCs for islet proteins in most of the molecular weight regions, whereas + type 2 diabetic patients had PBMCs responsive to the same molecular weight proteins. Ab+ type 2 diabetic patients appear to be heterogeneous with respect to cellular reactivity to islet proteins. Some subjects demonstrate PBMC responses similar to those of 'classic' type 1 diabetic patients, whereas others have PBMC responses potentially distinct from type 1 diabetic patients.

AB - Type 1 diabetes is a cell-mediated autoimmune disease characterized by autoantibody and peripheral blood mononuclear cell (PBMC) reactivity to islet cell proteins. Type 2 diabetes is not an autoimmune disease but rather results from both insulin resistance and a nonautoimmune insulin secretory defect. There is, however, a group of phenotypic type 2 diabetic patients who have islet autoantibodies that are similar to those of type 1 diabetic patients. In this study, we investigated, using cellular immunoblotting, whether type 2 diabetic patients positive for islet autoantibodies have PBMC responses to islet proteins. We observed that autoantibody negative (Ab-) type 2 diabetic patients (n = 9) and normal control subjects (n = 12) demonstrated PBMCs responsive to 0-3 molecular weight regions. In contrast, autoantibody positive (Ab+) type 2 diabetic patients (n = 11) demonstrated PBMC responses to 3-18 molecular weight regions, similar to that of type 1 diabetic patients (responsive to 4-18 molecular weight regions). PBMCs from over 90% of the Ab+ type 2 and type 1 diabetic patients were observed to proliferate to islet proteins in the vicinity of 97 kDa. In contrast, 65-90% of type 1 diabetic patients had responsive PBMCs for islet proteins in most of the molecular weight regions, whereas + type 2 diabetic patients had PBMCs responsive to the same molecular weight proteins. Ab+ type 2 diabetic patients appear to be heterogeneous with respect to cellular reactivity to islet proteins. Some subjects demonstrate PBMC responses similar to those of 'classic' type 1 diabetic patients, whereas others have PBMC responses potentially distinct from type 1 diabetic patients.

UR - http://www.scopus.com/inward/record.url?scp=0032940245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032940245&partnerID=8YFLogxK

U2 - 10.2337/diabetes.48.5.983

DO - 10.2337/diabetes.48.5.983

M3 - Article

VL - 48

SP - 983

EP - 988

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 5

ER -